Background: Necrotizing enterocolitis (NEC) is a major morbidity and cause of mortality in preterm neonates. Probiotics seem to have a beneficial role in preventing NEC, which is confirmed in meta-analyses of randomized controlled trials (RCTs). We therefore aimed to review and confirm the efficacy of probiotics in preterm neonates obtained in observational studies. Objective: To assess the effects of prophylactic probiotics in preterm infants. Methods: A meta-analysis was performed searching PubMed, EMBASE, CENTRAL (the Cochrane Library) and www.clinicaltrials.gov. Reference lists of reviews of RCTs were also searched. Included studies were observational studies that enrolled preterm infants <37 weeks of gestational age. Trials were included if they administered any probiotics and measured at least one clinical outcome (e.g. NEC, all-cause mortality, sepsis or long-term development scores). Two authors extracted characteristics and outcomes from included studies. The Newcastle-Ottawa Scale was used for quality assessment. A random-effects meta-analysis model was used, and heterogeneity was assessed by the I2 test. Results: We included 12 studies with 10,800 premature neonates (5,144 receiving prophylactic probiotics and 5,656 controls). The meta-analysis showed a significantly decreased incidence of NEC (risk ratio, RR = 0.55, 95% confidence interval, 95% CI, 0.39-0.78; p = 0.0006) and mortality (RR = 0.72, 95% CI, 0.61-0.85; p < 0.0001). Sepsis did not differ significantly between the two groups (RR = 0.86, 95% CI, 0.74-1.00; p = 0.05). Conclusions: Probiotic supplementation reduces the risk of NEC and mortality in preterm infants. The effect sizes are similar to findings in meta-analyses of RCTs. However, the optimal strain, dose and timing need further investigation.

Keywords:
Meta-analysis, Mortality, Probiotics, Preterm neonates, Necrotizing enterocolitis, Observational studies
1.
Deshpande G, Rao S, Patole S: Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet 2007;369:1614-1620.
2.
Henry MCW, Moss RL: Necrotizing enterocolitis. Annu Rev Med 2009;60:111-124.
3.
Neu J: Necrotizing enterocolitis: the mystery goes on. Neonatology 2014;106:289-295.
4.
Berman L, Moss RL: Necrotizing enterocolitis: an update. Semin Fetal Neonatal Med 2011;16:145-150.
5.
Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, FAO/WHO, 2002.
6.
Soll RF: Probiotics: are we ready for routine use? Pediatrics 2010;125:1071-1072.
7.
Alfaleh K, Anabrees J: Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2014;4:CD005496.
8.
Higgins JPT, Sally Green S (eds): Cochrane Handbook for Systematic Reviews of Interventions. Chichester, Wiley, 2008.
9.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62:e1-e34.
10.
Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al: Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg 1978;187:1.
11.
Wells G, Shea B, O'Connel D, Peterson J, Welch V, Losos M, et al: The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses 2013. Ottawa, University of Ottawa, 2013.
12.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
13.
Ozen M, Elmas A, Ormeci AR, Dinleyici EC: Prophylactic probiotic supplementation not only decreases the incidence of NEC and mortality but also nosocomial infections in neonates in a cohort study. Int Symp Probiotics Prebiotics Pediatr, Istanbul, 2012, p 91.
14.
Li L, Wu B, Gao X, Wang S, Zheng Z, Xu J: Role of probiotics in the prevention of neonatal necrotizing enterocolitis: a case-control study (in Chinese). Chin J Contemp Pediatr 2006;8:464-466.
15.
Bonsante F, Iacobelli S, Gouyon J-B: Routine probiotic use in very preterm infants: retrospective comparison of two cohorts. Am J Perinatol 2013;30:41-46.
16.
Dang S, Shook L, Garlitz K, Hanna M, Desai N: Nutritional outcomes with implementation of probiotics in preterm infants. J Perinatol 2015;35:447-450.
17.
Härtel C, Pagel J, Rupp J, Bendiks M, Guthmann F, Rieger-Fackeldey E, et al: Prophylactic use of Lactobacillus acidophilus/Bifidobacterium infantis probiotics and outcome in very low birth weight infants. J Pediatr 2014;165:285-289.e1.
18.
Hoyos AB: Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis 1999;3:197-202.
19.
Hunter C, Dimaguila MAVT, Gal P, Wimmer JE, Ransom JL, Carlos RQ, et al: Effect of routine probiotic, Lactobacillus reuteri DSM 17938, use on rates of necrotizing enterocolitis in neonates with birthweight <1,000 grams: a sequential analysis. BMC Pediatr 2012;12:142.
20.
Janvier A, Malo J, Barrington KJ: Cohort study of probiotics in a North American neonatal intensive care unit. J Pediatr 2014;164:980-985.
21.
Lambæk I, Fonnest G, Gormsen M, Greisen G: Routine probiotic prophylaxis for necrotising enterocolitis in very preterm infants. A planned historically controlled study. Dan Med J, submitted.
22.
Li D, Rosito G, Slagle T: Probiotics for the prevention of necrotizing enterocolitis in neonates: an 8-year retrospective cohort study. J Clin Pharm Ther 2013;38:445-449.
23.
Luoto R, Matomäki J, Isolauri E, Lehtonen L: Incidence of necrotizing enterocolitis in very-low-birth-weight infants related to the use of Lactobacillus GG. Acta Paediatr 2010;99:1135-1138.
24.
Repa A, Thanhaeuser M, Endress D, Weber M, Kreissl A, Binder C, et al: Probiotics (Lactobacillus acidophilus and Bifidobacterium bifidum) prevent NEC in VLBW infants fed breast milk but not formula. Pediatr Res 2015;77:381-388.
25.
Yamashiro Y, Nagata S: Beneficial microbes for premature infants, and children with malignancy undergoing chemotherapy. Benef Microbes 2010;357-365.
26.
Zampieri N, Pietrobelli A, Biban P, Soffiati M, Dall'agnola A, Camoglio FS: Lactobacillus paracasei subsp. paracasei F19 in Bell's stage 2 of necrotizing enterocolitis. Minerva Pediatr 2013;65:353-360.
27.
Wang Q, Dong J, Zhu Y: Probiotic supplement reduces risk of necrotizing enterocolitis and mortality in preterm very low-birth-weight infants: an updated meta-analysis of 20 randomized, controlled trials. J Pediatr Surg 2012;241-248.
28.
Fanaro S, Chierici R, Guerrini P, Vigi V: Intestinal microflora in early infancy: composition and development. J Paediatr 2003;48-55.
29.
Schulzke SM, Deshpande GC, Patole SK: Neurodevelopmental outcomes of very low-birth-weight infants with necrotizing enterocolitis: a systematic review of observational studies. Arch Pediatr Adolesc Med 2007;161:583-590.
30.
Schmolzer G, Urlesberger B, Haim M, Kutschera J, Pichler G, Ritschl E, et al: Multi-modal approach to prophylaxis of necrotizing enterocolitis: clinical report and review of literature. Pediatr Surg Int 2006;573-580.
31.
Deshpande GC, Rao SC, Keil AD, Patole SK: Evidence-based guidelines for use of probiotics in preterm neonates. BMC Med 2011;9:92.
32.
Ofek Shlomai N, Deshpande G, Rao S, Patole S: Probiotics for preterm neonates: what will it take to change clinical practice? Neonatology 2013;64-70.
33.
Modi N: Probiotics and necrotising enterocolitis: the devil (as always) is in the detail. Commentary on N Ofek Shlomai et al: Probiotics for preterm neonates: what will it take to change clinical practice? (Neonatology 2014;105:64-70). Neonatology 2014;105:71-73.
34.
Jacobs SE, Tobin JM, Opie GF, Donath S, Tabrizi SN, Pirotta M, et al: Probiotic effects on late-onset sepsis in very preterm infants: a randomized controlled trial. Pediatrics 2013;132:1055-1062.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.